Jagsonpal Pharmaceuticals Ltd

₹ 333 -2.20%

27 Jun - close price

jagsonpal.com BSE: 507789 NSE: JAGSNPHARM

About

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients^[1]

Key Points

Business Overview:^[1]^[2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands

Website BSE NSE

Market Cap ₹ 881 Cr.
Current Price ₹ 333
High / Low ₹ 515 / 270
Stock P/E 39.2
Book Value ₹ 70.9
Dividend Yield 1.50 %
ROCE 17.0 %
ROE 13.0 %
Face Value ₹ 5.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 54.5%
Debtor days have improved from 25.8 to 19.2 days.

Cons

Promoter holding has decreased over last quarter: -0.39%
The company has delivered a poor sales growth of 4.58% over past five years.
Earnings include an other income of Rs.9.28 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores

	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	42.84	54.05	59.49	54.47	51.23	60.60	60.53	60.14	55.45	60.15	57.83	47.23	43.49
	37.72	44.77	50.09	48.85	50.45	53.42	47.62	51.50	50.01	51.52	49.46	43.83	40.82
Operating Profit	5.12	9.28	9.40	5.62	0.78	7.18	12.91	8.64	5.44	8.63	8.37	3.40	2.67
OPM %	11.95%	17.17%	15.80%	10.32%	1.52%	11.85%	21.33%	14.37%	9.81%	14.35%	14.47%	7.20%	6.14%
	2.66	0.82	0.28	1.95	0.37	-3.15	1.12	1.74	2.56	2.00	2.27	2.52	2.49
Interest	0.13	0.11	0.06	0.06	0.06	0.01	0.03	0.18	0.20	0.15	0.22	0.23	0.22
Depreciation	0.26	0.28	0.23	0.37	0.65	0.19	0.20	0.33	0.48	0.39	0.46	0.41	0.40
Profit before tax	7.39	9.71	9.39	7.14	0.44	3.83	13.80	9.87	7.32	10.09	9.96	5.28	4.54
Tax %	30.85%	29.45%	30.24%	24.23%	31.82%	23.50%	24.49%	21.07%	23.50%	25.87%	25.00%	24.81%	21.59%
	5.10	6.85	6.56	5.41	0.31	2.92	10.41	7.79	5.60	7.48	7.47	3.96	3.55
EPS in Rs	1.95	2.61	2.50	2.07	0.12	1.11	3.97	2.97	2.14	2.86	2.85	1.51	1.34
Raw PDF

Profit & Loss

Figures in Rs. Crores

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	166	144	138	143	144	127	167	159	188	218	237	209
	156	133	129	132	138	138	157	150	169	192	202	186
Operating Profit	10	11	9	12	6	-11	9	9	19	26	35	23
OPM %	6%	7%	6%	8%	4%	-9%	6%	5%	10%	12%	15%	11%
	0	0	0	1	13	0	1	3	4	3	2	9
Interest	5	5	4	5	3	1	1	1	1	0	0	1
Depreciation	3	3	3	3	2	0	1	1	1	2	1	2
Profit before tax	3	3	2	4	14	-12	9	9	22	27	35	30
Tax %	28%	16%	30%	20%	18%	1%	20%	16%	22%	29%	23%	25%
	2	2	1	3	12	-12	7	8	17	19	27	22
EPS in Rs	0.70	0.81	0.45	1.24	4.53	-4.41	2.76	3.00	6.51	7.20	10.20	8.50
Dividend Payout %	72%	62%	22%	8%	2%	-2%	9%	17%	15%	56%	49%	59%

Compounded Sales Growth
10 Years:	4%
5 Years:	5%
3 Years:	4%
TTM:	-12%

Compounded Profit Growth
10 Years:	27%
5 Years:	25%
3 Years:	10%
TTM:	-23%

Stock Price CAGR
10 Years:	35%
5 Years:	67%
3 Years:	29%
1 Year:	-10%

Return on Equity
10 Years:	8%
5 Years:	14%
3 Years:	16%
Last Year:	13%

Balance Sheet

Figures in Rs. Crores

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	85	85	82	85	97	85	91	98	109	120	146	174
	33	36	39	38	8	8	4	5	7	0	6	9
	21	22	19	22	25	23	28	31	35	31	30	21
Total Liabilities	153	156	154	159	143	130	136	147	164	164	195	217
	58	56	52	52	22	21	22	22	26	23	24	9
CWIP	2	2	0	0	0	3	4	4	0	0	0	0
Investments	0	0	0	0	0	0	0	11	15	51	1	0
	92	98	102	108	121	105	110	109	123	91	170	208
Total Assets	153	156	154	159	143	130	136	147	164	164	195	217

Cash Flows

Figures in Rs. Crores

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	12	8	4	9	-3	-2	31	11	28	7	47	35
	-3	-1	-0	-2	41	-3	-1	-11	-2	-26	-58	-25
	-8	-4	-1	-6	-34	-1	-6	-1	-7	-18	-0	-9
Net Cash Flow	0	2	2	1	5	-6	24	-0	19	-36	-11	2

Ratios

Figures in Rs. Crores

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	93	115	119	106	100	73	45	49	25	26	32	19
Inventory Days	127	173	176	246	295	307	164	191	134	122	81	68
Days Payable	28	29	42	60	56	54	59	76	82	76	64	35
Cash Conversion Cycle	192	259	252	292	339	325	150	164	77	72	49	53
Working Capital Days	130	155	171	169	174	173	76	66	45	59	36	59
ROCE %	6%	6%	5%	7%	3%	-10%	9%	9%	18%	20%	26%

Shareholding Pattern

Numbers in percentages

	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	70.34%	70.34%	70.34%	68.71%	68.71%	68.72%	68.72%	68.72%	68.72%	68.72%	68.48%	68.09%
	0.00%	0.11%	0.20%	0.00%	0.00%	0.13%	0.11%	0.10%	0.37%	0.38%	0.53%	0.73%
	0.00%	0.01%	0.00%	0.67%	0.68%	0.28%	0.77%	0.82%	0.82%	0.82%	0.82%	0.84%
	29.65%	29.54%	29.46%	30.61%	30.61%	30.85%	30.40%	30.34%	30.07%	30.07%	30.16%	30.33%
No. of Shareholders	14,655	14,353	20,031	17,100	16,194	14,952	14,535	14,084	13,782	16,041	15,785	16,282

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	69.17%	69.17%	69.17%	70.26%	70.34%	70.34%	68.71%	68.72%	68.09%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.73%
	0.00%	0.00%	0.00%	0.00%	0.01%	0.00%	0.67%	0.82%	0.84%
	30.83%	30.83%	30.83%	29.74%	29.66%	29.65%	30.61%	30.34%	30.33%
No. of Shareholders	10,469	10,738	10,453	9,064	9,047	12,546	17,100	14,084	16,282

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Feb 2024

Transcript

Notes
PPT
Nov 2023

Transcript

Notes
PPT
May 2023

Transcript

Notes
PPT
Feb 2023

Transcript

Notes
PPT
Feb 2022

Transcript

Notes
PPT